Komori
Japan Medical Dynamic Marketing (7600) · InitiativeProprietary products accounted for a lower proportion of sales

Increasing the proportion of revenue from proprietary products and in-house manufacturing capacity

First written in FY2016. 9 of 28 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.

28entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2017-Q1 – FY2018-Q3OtherFY2019-Q1 – FY2020-Q2OtherFY2020 – FY20242016: 320162017: 420172018: 320182019: 320192020: 420202021: 320212022: 020222023: 220232024: 320242025: 120252026: 22026
Same theme, other companies
Margin Improvement Through a Higher In-House Manufacturing Ratio and Integrated Sales and ManufacturingA theme 4 companies write about · 0 as a headwind · 4 as a tailwind

0 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026Proprietary products accounted for a lower proportion of salesAnnual report

    「The proportion of proprietary product sales in consolidated net sales declined from the 80% range to 79.2%.」

    The proportion of proprietary products in sales declined from 80.7% to 79.2%.
  2. 2026-05-08SoftenedEarnings

    「The proportion of proprietary product sales in consolidated net sales declined from the 80% range to 79.2%.」

    The proportion of proprietary product sales declined from the previous fiscal year. At the same time, increasing this proportion was identified as a future measure.
  3. FY2026-H1Proprietary products accounted for a lower proportion of salesAnnual report

    「The proportion of proprietary products in consolidated sales was 79.6%, compared with 80.9% in the same period of the previous year.」

    The proportion of proprietary products in sales declined from 80.9% in the same period of the previous year to 79.6%.
  4. FY2025-H1AdvancedAnnual report

    「The proportion of proprietary products in consolidated sales was 80.9%, compared with 80.1% in the same period of the previous year.」

    The proportion of proprietary products in sales rose from 80.1% in the same period of the previous year to 80.9%.
  5. FY2024Proprietary products accounted for a lower proportion of salesAnnual report

    「The proportion of proprietary products in consolidated sales was 80.2%, compared with 80.6% in the previous consolidated fiscal year.」

    The proportion of proprietary products in sales declined from 80.6% in the previous year to 80.2%.
  6. FY2024-Q3The proportion of proprietary products in sales declined year on yearAnnual report

    「The proportion of proprietary products in consolidated sales was 80.3%, compared with 80.8% in the same quarter of the previous year.」

    The proportion of proprietary products in sales declined from 80.8% in the previous year to 80.3%.
  7. FY2024-Q2The proportion of proprietary products in sales declined year on yearAnnual report

    「The proportion of proprietary products in consolidated sales was 80.1%, compared with 80.3% in the same quarter of the previous year.」

    The proportion of proprietary products in sales declined from 80.3% in the same quarter of the previous year to 80.1%.
  8. FY2024-Q1The proportion of proprietary products in sales was flat year on yearAnnual report

    「The proportion of proprietary products in consolidated sales was 80.1%, unchanged from 80.1% in the same quarter of the previous year.」

    Proprietary products accounted for 80.1% of sales, at the same level as in the same quarter of the previous year.
  9. FY2022-Q2The lower proprietary-product sales mix and deterioration in the cost ratio continuedAnnual report

    「Proprietary products accounted for 79.6% of sales due to the recovery in US sales and other factors, while the cost of sales ratio was 32.2%, compared with 32.0% in the same quarter of the previous year, due to exchange-rate fluctuations and other factors.」

    Proprietary products accounted for 79.6% of sales, down from the 80% range in the same period of the previous year. The cost of sales ratio also rose from 32.0% in the same period of the previous year to 32.2%.
  10. FY2022-Q1The proprietary-product sales mix declined, but the cost of sales ratio improved slightlyAnnual report

    「Due to the recovery in US sales and other factors, proprietary products accounted for 80.1% of sales, and the cost of sales ratio was 32.0%, compared with 32.3% in the same quarter of the previous year.」

    While the proportion of proprietary products in sales declined from 83.3% in the same period of the previous year to 80.1%, the cost of sales ratio improved slightly from 32.3% to 32.0%.
  11. FY2021-Q3Deterioration in the cost ratio due to the lower proportion of proprietary products in sales continuedAnnual report

    「The proportion of proprietary products in sales declined due to lower US sales and other factors related to the impact of COVID-19, worsening the cost of sales ratio to 31.9%, from 28.6% in the same quarter of the previous year.」

    The proportion of proprietary products in sales continued to decline due to lower US sales and other factors, and the cost of sales ratio deteriorated from 28.6% in the same period of the previous year to 31.9%.
  12. FY2021-Q2Deterioration in the cost ratio due to the lower proprietary-product mix continuedAnnual report

    「Cost of sales was affected by factors including the decline in the proportion of proprietary products in sales, which worsened the cost of sales ratio. The cost of sales ratio was 32.0%, compared with 28.9% in the same quarter of the previous year.」

    The decline in the proportion of proprietary products in sales continued to be cited as a factor behind the deterioration in the cost ratio, and the cost of sales ratio rose from 28.9% in the same period of the previous year to 32.0%.
  13. FY2021-Q1The lower proprietary-product mix and deterioration in the cost ratio continuedAnnual report

    「Cost of sales was affected by factors including the decline in the proportion of proprietary products in sales, which worsened the cost of sales ratio. The cost of sales ratio was 32.3%, compared with 29.0% in the same quarter of the previous year.」

    The decline in the proportion of proprietary products in sales was cited as a factor behind the deterioration in the cost ratio, and the cost of sales ratio rose from 29.0% in the same period of the previous year to 32.3%.
  14. FY2020A lower proprietary-product mix coexisted with the benefit of lower manufacturing costsAnnual report

    「Although the gradual reduction of reimbursement prices in Japan and the decline in the proportion of proprietary products in sales contributed to deterioration in the cost of sales ratio, lower manufacturing costs resulting from expanded in-house manufacturing capacity at the US subsidiary and increased overseas sourcing, among other factors, reduced the cost of sales ratio to 29.2%, from 29.4% in the previous consolidated fiscal year.」

    The decline in the proportion of proprietary products in sales contributed to deterioration in the cost ratio, but lower costs from expanded in-house manufacturing capacity and increased overseas sourcing improved the overall cost of sales ratio.
  15. FY2020-Q3AdvancedAnnual report

    「The cost of sales ratio declined to 28.6%, from 29.3% in the same quarter of the previous year, due to lower manufacturing costs resulting from expanded in-house manufacturing capacity at the US subsidiary and increased overseas sourcing, among other factors.」

    Although no figure was provided for the proportion of proprietary products in sales, lower manufacturing costs resulting from expanded in-house manufacturing capacity at the US subsidiary and increased overseas sourcing were confirmed, and the cost of sales ratio declined from 29.3% in the same quarter of the previous year to 28.6%.
  16. FY2020-Q2The proprietary-product mix continued to decline, while the manufacturing cost ratio improved slightlyAnnual report

    「Although the proportion of proprietary products in sales declined to 83.0%, from 87.6% in the same quarter of the previous year, the cost of sales ratio was 28.9%, compared with 29.0%, due to lower manufacturing costs resulting from expanded in-house manufacturing capacity at the US subsidiary and increased overseas sourcing, among other factors.」

    The proportion of proprietary products in sales declined from 87.6% in the same quarter of the previous year to 83.0%, but the cost of sales ratio improved slightly from 29.0% to 28.9% due to lower manufacturing costs resulting from expanded in-house manufacturing capacity at the US subsidiary and increased overseas sourcing.
  17. FY2020-Q1Lower proprietary-product mix and deteriorating cost ratioAnnual report

    「Despite the cost reductions achieved through expanded in-house manufacturing capacity in North America and stronger overseas procurement, the cost of sales ratio was 29.0%, compared with 28.4% in the same quarter of the previous year, due to the decline in the proportion of revenue from proprietary products to 83.3% from 88.0% and the impact of reimbursement price reductions.」

    The proportion of proprietary products in sales declined from 88.0% in the same quarter of the previous year to 83.3%, while the cost of sales ratio rose from 28.4% to 29.0%.
  18. FY2019-Q3Lower proprietary-product mix and deteriorating cost ratioAnnual report

    「The cost of sales ratio was 29.3%, compared with 27.6% in the same quarter of the previous year, due to the decline in the proportion of proprietary products in sales to 86.6%, from 89.2%, and the impact of lower reimbursement prices.」

    The proportion of proprietary products in sales declined from 89.2% in the same quarter of the previous year to 86.6%, while the cost of sales ratio rose from 27.6% to 29.3%.
  19. FY2019-Q2Lower proprietary-product mix and deteriorating cost ratioAnnual report

    「The cost of sales ratio was 29.0%, compared with 27.5% in the same quarter of the previous year, due to the decline in the proportion of proprietary products in sales to 87.6%, from 89.4%, and the impact of lower reimbursement prices.」

    The proportion of proprietary products in sales declined from 89.4% in the same quarter of the previous year to 87.6%, while the cost of sales ratio rose from 27.5% to 29.0%.
  20. FY2019-Q1Lower proprietary-product mix and deteriorating cost ratioAnnual report

    「The cost of sales ratio was 28.4%, compared with 27.5% in the same quarter of the previous year, due to the decline in the proportion of proprietary products in sales to 88.0%, from 89.7%, and the impact of lower reimbursement prices.」

    The proportion of proprietary products in sales declined from 89.7% in the same quarter of the previous year to 88.0%, while the cost of sales ratio rose from 27.5% to 28.4%.
  21. FY2018-Q3AdvancedAnnual report

    「Despite the impact of the weaker yen and lower reimbursement prices, the cost of sales ratio improved to 27.6%, from 27.8% in the same quarter of the previous year, due to lower manufacturing costs and the increase in the proportion of proprietary products in sales to 89.2%, from 87.5%.」

    The proportion of proprietary products in sales rose from 87.5% in the same quarter of the previous year to 89.2%, and the cost of sales ratio also improved from 27.8% to 27.6%, together with the benefit of lower manufacturing costs.
  22. FY2018-Q2AdvancedAnnual report

    「Despite the impact of the weaker yen and lower reimbursement prices, the cost of sales ratio improved to 27.5%, from 27.9% in the same quarter of the previous year, due to lower manufacturing costs and the increase in the proportion of proprietary products in sales to 89.4%, from 87.3%.」

    The proportion of proprietary products in sales rose from 87.3% in the same period of the previous year to 89.4%, and the cost of sales ratio also improved from 27.9% to 27.5%, together with the benefit of lower manufacturing costs.
  23. FY2018-Q1AdvancedAnnual report

    「As a result, despite lower reimbursement prices, the cost of sales ratio improved to 27.5% (29.3% in the same quarter of the previous year), reflecting the effect of lower manufacturing costs and the rise in the ratio of sales from proprietary products to 89.7% (87.1% in the same quarter of the previous year).」

    In the cumulative first-quarter period, the proportion of proprietary products in sales rose from 87.1% in the same period of the previous year to 89.7%, and the cost of sales ratio also improved, together with the benefit of lower manufacturing costs.
  24. FY2017AdvancedAnnual report

    「To improve profitability, we will raise the proportion of proprietary products in sales while also expanding in-house manufacturing at ODEV. As a result, despite lower reimbursement prices, the proportion of proprietary products in sales rose to 87.5%, compared with 85.1% in the previous consolidated fiscal year. Together with the impact of the stronger yen and other factors, this improved the cost of sales ratio to 28.8%, from 29.3% in the previous consolidated fiscal year.」

    The proportion of proprietary products in sales rose from 85.1% to 87.5%, while the cost of sales ratio improved from 29.3% to 28.8%.
  25. FY2017-Q3AdvancedAnnual report

    「As a result, the ratio of sales from proprietary products rose to 87.5% (85.1% in the same quarter of the previous year), and the cost of sales ratio was 27.8% (29.0% in the same quarter of the previous year), despite a reduction in reimbursement prices, partly due to the stronger yen and other factors.」

    The proportion of proprietary products in sales rose from 85.1% in the same quarter of the previous year to 87.5%. Progress in expanding in-house manufacturing itself is not described, but the increase in the proprietary-product mix is reported.
  26. FY2017-Q2AdvancedAnnual report

    「As a result, proprietary products accounted for 87.3% of sales, up from 85.0% in the same quarter of the previous year.」

    The proportion of proprietary products in sales rose from 85.0% in the same quarter of the previous year to 87.3%.
  27. FY2017-Q1AdvancedAnnual report

    「As a result, proprietary products accounted for 87.1% of sales, up from 84.0% in the same quarter of the previous year.」

    The proportion of proprietary products in sales rose from 84.0% in the same quarter of the previous year to 87.1%.
  28. FY2016First statedAnnual report

    「To improve profitability, we will raise the proportion of proprietary products in sales while also expanding in-house manufacturing at ODEV.」

    The company positions increasing the proprietary-product mix and expanding manufacturing at ODEV as measures to improve profitability.
Moved together

"Expansion of the North American Business and Development of the Overseas Trading Business" moved the same way as this thread, in the same document, in 10 of its 28 moves.

10109875★123456
  1. ★This thread
  2. 1Expansion of the North American Business and Development of the Overseas Trading Business10×
  3. 2Expansion of North American sales and the impact of new customers and new products10×
  4. 3Return to Revenue and Profit Growth9×
  5. 4Higher proportion of sales from proprietary products8×
  6. 5Maintaining profitable high growth in Japan and North America while balancing growth and efficiency7×
  7. 6Cost Efficiency Through Expanded In-House Manufacturing and Operational Reform5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Japan Medical Dynamic Marketing's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Earnings of 2026-05-08: "Softened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Increasing the proportion of revenue from proprietary products and in-house manufacturing capacity | Japan Medical Dynamic Marketing,INC. (7600) | Komori